Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a 11.11 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $3.34 million which beat the analyst consensus estimate of $2.38 million by 40.34 percent. This is a 119.30 percent increase over sales of $1.52 million the same period last year.
‘UK will require new homes to have EV chargers starting in 2022’ – TechCrunch
https://twitter.com/TechCrunch/status/1462751762704646145